<DOC>
	<DOCNO>NCT02259179</DOCNO>
	<brief_summary>This Phase 1 , open-label , randomize , single-dose , 2-way crossover study healthy adult subject assess bioequivalence naltrexone SR/bupropion SR combination trilayer tablet prepare two different manufacture site . The pharmacokinetics two drug product evaluate separately feed fast state .</brief_summary>
	<brief_title>Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers</brief_title>
	<detailed_description />
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Bupropion hydrochloride , naltrexone hydrochoride drug combination</mesh_term>
	<criteria>1 . Male female , 18 60 year age , inclusive 2 . Be good general health , without clinically significant medical history , physical examination finding , laboratory result Screening Day 1 3 . Body mass index ( BMI ) 18 30 kg/m2 , inclusive , Screening 1 . Acute ( within 28 day Day 1 ) chronic illness 2 . History ( within last 20 year ) seizures , cranial trauma , bulimia , anorexia nervosa , condition may predispose subject seizure ; previous medical treatment anticonvulsant type 3 . History mania current diagnosis active psychosis 4 . Acute depressive illness , include new onset depression acute exacerbation symptom 5 . Use prescription medication within 14 day prior Day 1 , exception hormonal contraceptive hormonal replacement therapy ( HRT ) stable dose least 28 day prior Day 1 6 . Use overthecounter medication , include dietary/nutritional herbal supplement , within 24 hour prior study drug intake Day 1 7 . Use bupropion naltrexonecontaining product within 28 day prior Day 1 , history hypersensitivity intolerance naltrexone bupropion 8 . Have donate blood significant blood loss within 90 day prior Day 1 ; donate plasma within 7 day prior Day 1 9 . Hemoglobin concentration &lt; 11 g/dL Screening 10 . Blood pressure &gt; 140/90 mm Hg Screening Day 1 11 . Women pregnant try become pregnant , positive pregnancy test Screening Day 1 , currently breastfeed , childbearing potential ( include perimenopausal woman menstrual period within 1 year prior Day 1 ) willing practice effective birth control . Women surgically sterile ( include bilateral tubal ligation , tubal occlusion , hysterectomy oophorectomy ) consider childbearing potential . 12 . Drug alcohol abuse dependence within 6 month prior Screening , positive urine drug screen Screening Day 1 13 . Regular daily use tobacco product , include inhale tobacco ( e.g. , cigarette , cigar , pipe ) , chew tobacco snuff , nicotine replacement product ( include electronic cigarette nicotine vaporizer ) within 28 day prior Day 1 14 . Unwilling refrain consumption citrus product ( e.g. , whole fruit , juice product contain orange , grapefruit , pomelo ) , alcohol caffeine/xanthinecontaining food beverages 48 hour study drug intake treatment period ( Days 1 15 ) 72 hour postdose ( Days 4 18 ) 15 . Inability unwillingness consume standardize highfat breakfast provide study clinic Days 1 15 16 . Inability comply require study procedure schedule , inability speak read English , unwillingness inability give write informed consent 17 . Employee immediate family member sponsor ( designee ) study site research staff 18 . Use investigational drug , device , procedure within 30 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Contrave</keyword>
	<keyword>Antiobesity agent</keyword>
	<keyword>Antiobesity drug</keyword>
	<keyword>Weight loss drug</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>